Health Sciences Acquisitions Corp 2 HSAQ
We take great care to ensure that the data presented and summarized in this overview for Health Sciences Acquisitions Corp 2 is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HSAQ
View allLatest Institutional Activity in HSAQ
Top Purchases
Top Sells
About HSAQ
Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.
Insider Transactions at HSAQ
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 03
2025
|
Darren Sherman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
40,340
-4.35%
|
$80,680
$2.72 P/Share
|
|
Aug 25
2025
|
Eric S Fain Director |
BUY
Open market or private purchase
|
Indirect |
5,760
+7.44%
|
$11,520
$2.61 P/Share
|
|
Aug 25
2025
|
Andrew Lawrence Taylor Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+0.41%
|
$4,000
$2.55 P/Share
|
|
Aug 25
2025
|
Darren Sherman Director |
BUY
Open market or private purchase
|
Direct |
3,000
+0.32%
|
$6,000
$2.62 P/Share
|
|
Aug 21
2025
|
David P Hochman Director |
BUY
Open market or private purchase
|
Direct |
6,000
+0.91%
|
$12,000
$2.49 P/Share
|
|
Aug 07
2025
|
Connealy Pamela Yanchik Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+23.54%
|
-
|
|
Aug 07
2025
|
Darren Sherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+11.5%
|
-
|
|
Aug 07
2025
|
Jason Aryeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+12.25%
|
-
|
|
Aug 07
2025
|
Andrew Lawrence Taylor Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+14.27%
|
-
|
|
Aug 07
2025
|
David Pacitti Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+25.01%
|
-
|
|
Aug 07
2025
|
David P Hochman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
100,000
+18.2%
|
-
|
|
Aug 07
2025
|
David P Hochman Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+13.41%
|
-
|
|
Aug 07
2025
|
Chris Cleary Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+28.53%
|
-
|
|
Aug 07
2025
|
Eric S Fain Director |
BUY
Grant, award, or other acquisition
|
Indirect |
7,500
+11.37%
|
-
|
|
Aug 07
2025
|
Eric S Fain Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
-
|
|
Aug 07
2025
|
John Prosper Mack Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+27.13%
|
-
|
|
Aug 07
2025
|
Joshua Aiello Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+43.69%
|
-
|
|
Aug 04
2025
|
David P Hochman Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+5.42%
|
$40,000
$2.75 P/Share
|
|
Aug 01
2025
|
Perceptive Advisors LLC |
BUY
Open market or private purchase
|
Indirect |
700,000
+11.68%
|
$1,400,000
$2.75 P/Share
|
|
Jun 26
2025
|
Eric S Fain Director |
SELL
Open market or private sale
|
Indirect |
2,683
-5.0%
|
$8,049
$3.05 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 857K shares |
|---|---|
| Grant, award, or other acquisition | 888K shares |
| Exercise of conversion of derivative security | 11.7K shares |
| Open market or private sale | 2.68K shares |
|---|---|
| Payment of exercise price or tax liability | 301K shares |